Some patients With breast cancer can forego axillary dissection.sentinel lymph node Sentinel lymph node
The first lymph node to receive lymph fluid from a tumor. If the sentinel node is cancer-free, then it is likely that the cancerous cells have not metastasized.
Mentioned in: Vulvar Cancer dissection (SLND) plus axillary lymph node dissection axillary lymph node dissection Surgery The excision of the lymph nodes in the armpit, a procedure commonly performed with mastectomy for breast CA. See Breast cancer. (ALND) or SLND alone. Complete ALND for patients with breast cancer has been standard practice; how-ever, results of the new study could help end a long-running debate over the role of SLND in the management of early breast cancer.
The 900-patient randomized, prospective trial found the five-year overall survival rate was 91.8% for patients with SLND and ALND compared to 92.5% with SLND alone, and the five-year disease-free survival was 82.2% with SLND and ALND compared to 83.9% with SLND alone. The results apply only to a subgroup of patients with the clinical characteristics of those in the trial: stage T1-T2 breast cancer with no palpable adenopathy and one or two sentinel nodes treated with breast-conserving surgery, whole-breast irradiation, and adjuvant systemic therapy. Even limited to this subgroup, the study findings could improve clinical outcomes in thousands of women each year by reducing ALND and its complications and improving quality of life with no decrease in survival.
Giuliano, A.E., Hunt, K.K., Ballman, K.V., Beitsch, P.D., Whitworth, P.W., Blumencranz, P.W, ... Morrow, M. (2011). Axillary ax·il·lar·y
Relating to the axilla.
Located in or near the armpit.
Mentioned in: Mastectomy
of or pertaining to the armpit. dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial randomized clinical trial,
n a clinical study where volunteer participants with comparable characteristics are randomly assigned to different test groups to compare the efficacy of therapies. . JAMA, 305, 569-575.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||just in|
|Article Type:||Brief article|
|Date:||Apr 1, 2011|
|Previous Article:||Rose Mary's lessons continue in those she mentored.|
|Next Article:||Mouse studies suggest prognostic test for prostate cancer.|